Metfogamma

Metformin Hydrochloride, the active ingredient in Metfogamma, is a biguanide presented as an oral tablet for oral use. It is employed to lower elevated blood glucose levels in adults with type 2 diabetes mellitus. The medication improves insulin sensitivity and reduces hepatic glucose output, helping patients achieve better glycemic control.

GNH USA supplies Metfogamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this essential antidiabetic agent.

Metfogamma is a biguanide that acts on glucose metabolism to control hyperglycaemia in diabetes and related conditions.

Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial glucose levels. Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when used as part of lifestyle intervention. Polycystic ovary syndrome (off‑label): reduces insulin resistance and may help restore ovulatory cycles.

Metfogamma may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite. - Diarrhoea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient metallic sensation in the mouth. - Weight loss: modest reduction in body weight over time. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal accumulation of lactate. - Severe hypoglycaemia: usually when combined with other glucose‑lowering agents. - Hepatotoxicity: rare liver injury. - Pancreatitis: inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Metfogamma, several safety considerations should be reviewed.

Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. Lactic acidosis risk: contraindicated in patients with significant hepatic disease or conditions predisposing to hypoxia. Alcohol consumption: limit intake to reduce the risk of lactic acidosis. Pregnancy and lactation: prescribe only if potential benefits outweigh risks. Drug interactions: review concomitant medications that may affect metformin clearance. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metfogamma can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure. - Cimetidine: can increase metformin plasma concentrations. - Nitrates: may raise the risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Diuretics: can affect renal function and metformin clearance. - ACE inhibitors or ARBs: monitor renal function and electrolytes during combined therapy.